



## Review

# Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?



Michele Iudici<sup>a</sup>, Gianluca Moroncini<sup>b</sup>, Paola Cipriani<sup>c</sup>, Roberto Giacomelli<sup>c</sup>,  
Armando Gabrielli<sup>b</sup>, Gabriele Valentini<sup>a,\*</sup>

<sup>a</sup> Department of Clinical and Experimental Medicine, Rheumatology Section, Second University of Naples, Naples, Italy

<sup>b</sup> Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy

<sup>c</sup> Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, Italy

## ARTICLE INFO

## Article history:

Received 25 January 2015

Accepted 2 February 2015

Available online 21 February 2015

## Keywords:

Active SSc-ILD

First-line treatment

Second-line treatment

## ABSTRACT

Interstitial lung disease (ILD) affects about 90% of patients with systemic sclerosis (SSc). It is associated with a restrictive lung disease in only 30% of patients and is progressive in an even lower percentage. A low forced vital capacity at presentation, an extent of lung fibrosis >20% as detected by lung high-resolution computed tomography, high serum interleukin-6 levels, anti-topoisomerase I antibody positivity and diffuse cutaneous SSc are each associated with SSc-ILD progression. However, no such association is absolute. Treating patients with a recent deterioration of lung function may allow to capture those with active disease. To date, cyclophosphamide (CYC) is the only drug found to stabilize or improve lung function in randomized clinical trials, but its small beneficial effect is short lived. Therefore, immunosuppressive maintenance therapy after CYC treatment is warranted. At present, however, the best therapeutical strategy after CYC therapy both in responders and in non-responders to CYC is still controversial. Based on a review of the literature, we suggest an approach to the management of SSc-ILD.

© 2015 Published by Elsevier B.V.

## Contents

1. Introduction . . . . .	575
2. Which SSc-ILD patients should be treated? . . . . .	576
3. Which drug should be used first? . . . . .	576
3.1. Stem cell transplantation . . . . .	577
4. Can immunosuppressive treatment be stopped? . . . . .	577
5. Which drug can be used in patients unresponsive to first-line therapy? . . . . .	577
6. Conclusions . . . . .	577
Competing interests . . . . .	577
List of abbreviations . . . . .	577
Take-home messages . . . . .	577
Acknowledgments . . . . .	577
References . . . . .	578

\* Corresponding author at: Department of Clinical and Experimental Medicine, Rheumatology Section, Building 3, Via S. Pansini, 5, Second University of Naples, Naples, Italy. Tel.: +39 0815464487; fax: +39 0815666747.

E-mail addresses: [michele\\_iudici@hotmail.com](mailto:michele_iudici@hotmail.com) (M. Iudici), [g.moroncini@univpm.it](mailto:g.moroncini@univpm.it) (G. Moroncini), [paola.cipriani@cc.univaq.it](mailto:paola.cipriani@cc.univaq.it) (P. Cipriani), [roberto.giacomelli@univaq.it](mailto:roberto.giacomelli@univaq.it) (R. Giacomelli), [a.gabrielli@univpm.it](mailto:a.gabrielli@univpm.it) (A. Gabrielli), [gabriele.valentini@unina2.it](mailto:gabriele.valentini@unina2.it) (G. Valentini).

## 1. Introduction

Systemic sclerosis (SSc) is an autoimmune systemic disease characterized by endothelial dysfunction, immunological abnormalities and fibroblastic activation resulting in fibrosis of the skin and target internal organs [1,2]. It is associated to a shortened survival [3] most frequently related to interstitial lung disease (ILD) and pulmonary arterial hypertension [4]. Whereas the latter affects a minority of SSc patients [5,6],

ILD is a frequent complication of SSc. The prevalence of ILD varies depending on the method used to detect the disease and reaches figures as high as 90% when detected with lung high-resolution computed tomography (HRCT) [7]. Despite its high prevalence, however, SSc-ILD is not evolutive and does not affect survival in most cases [8]. Restrictive lung disease was identified in 32% of SSc patients enrolled in the European Scleroderma Trials and Research (EUSTAR) database [9]. Moreover, in a study based on the University of Pittsburgh Scleroderma Databank, it has been reported to be severe (i.e., with a FVC < 50% of predicted value) in 16% (i.e., about 50% of patients with restrictive lung disease) [10].

Unlike pulmonary arterial hypertension, which is commonly treated according to expert-based recommendations, SSc-ILD treatment is still debated [8,11]. To date, only cyclophosphamide (CYC) was found to be effective in stabilizing or improving lung function in randomized clinical trials [12,13], but its small beneficial effect seems to be short lived [14]. Therefore, immunosuppressive maintenance therapy to be introduced after CYC seems warranted [14]. Moreover, the best therapeutical strategy to undergo after CYC therapy both in responders and in non-responders to CYC is controversial [15].

Drawing together the data available in the literature, here we suggest a therapeutical approach to SSc-ILD.

## 2. Which SSc-ILD patients should be treated?

The prognosis of SSc-ILD is less severe than that of idiopathic pulmonary fibrosis [16]. Actually, most SSc-ILD patients experience a stable or slowly progressive course. However, some of them undergo a rapidly progressive loss of lung function, which mainly occurs in the first years from disease onset [10].

Various factors have long been known to be associated with ILD in patients with SSc, namely, anti-topoisomerase I antibody positivity [17], African American race [18] and other genetic or environmental factors [18,19]. Table 1 lists disease features, detectable at presentation and predictive of progressive ILD. They include an extent of lung fibrosis >20% as detected by lung HRCT with an FVC <70% of predicted in indeterminate cases [20,21], high serum interleukin-6 levels [22], a low FVC, anti-topoisomerase I antibody positivity, diffuse cutaneous SSc (dcSSc) and a low DLCO, which is also known to predict pulmonary hypertension [5,23,24], while anti-centromere antibodies positivity is a protective feature [23]. Somewhat unexpectedly, the histopathologic pattern (usual interstitial pneumonia as compared to non-specific interstitial pneumonia) [25] as well as the presence of active alveolitis as detected by bronchoalveolar lavage analysis [26] do not seem to predict an unfavorable disease course in SSc-ILD patients.

Of the features listed above, an HRCT score seems the most consistent. In fact, in a recent systematic review, the extent of fibrosis on lung HRCT scan was the only variable that independently predicts at a point in time both ILD progression and mortality [27].

Despite the statistical significance of each of the above listed associations, none of them fully discriminated between patients with a stable or slowly progressive course and those with a rapidly progressive loss of lung function. This holds true also for putative “protective” disease features. Indeed, the limited cutaneous subset [28] as well as “protective”

marker autoantibodies can be associated with clinically significant and evolutive ILD [29]. These evidence have so far hampered the development of an algorithm for the treatment of ILD in the single SSc patient [8], in particular in the early stages of the disease when the extent of fibrosis, as detectable by lung HRCT, may be limited.

A study of idiopathic ILD showed that, at presentation, the histologic pattern (i.e., usual interstitial pneumonia as opposed to non-specific interstitial pneumonia) is the most important prognostic marker, while changes in FVC together with initial lung diffusion for carbon monoxide (DLCO) and gender are the only independent prognostic factors during follow-up, and the morphological pattern provide no additional prognostic information [30]. Regarding SSc-ILD, Moore et al. [22] reported that the extent of fibrosis on lung HRCT at baseline independently predicts outcome, and that during follow-up the diffusing capacity for carbon monoxide divided by the alveolar volume (DLCO/VA) and FVC strongly predict outcome.

These data suggest the following patients be treated: (i) all patients presenting at first observation with either an extent of lung disease >20% on HRCT or an indeterminate extent of disease plus an FVC <70%, and (ii) during follow-up, all patients experiencing a significant decrease of DLCO (>15%) or FVC (>10%) or both, whatever the extent of lung involvement. Treating SSc-ILD patients who have only a decrease in DLCO is not at present warranted because DLCO is not considered a primary endpoint in ILD treatment due to both pathophysiological and variability reasons [31]. Nevertheless, it has been recently demonstrated that DLCO provides the best overall estimate of HRCT-measured SSc-ILD disease in the absence of pulmonary hypertension [32]. Therefore, the approach we propose is to treat patients with early disease in whom extensive damage has not yet occurred. This holds true also for patients with a disease duration >4 years given the finding of similar rates of progression of lung disease, irrespective of disease duration in patients enrolled in the placebo arm of the Scleroderma Lung Study [33].

## 3. Which drug should be used first?

A few years ago, experts from EUSTAR performed a systematic review of the literature ensuing in 14 evidence-based recommendations [34] and recommended treating patients affected by SSc-ILD with CYC. The recommendation was based on the data of two high quality randomized controlled trials on the efficacy of oral (the Scleroderma Lung Study) [12] or pulse (Fibrosing Alveolitis in Scleroderma Trials) [13] CYC compared to placebo. A further unblinded, randomized trial versus azathioprine and a number of observational studies also supported the effectiveness of CYC with or without oral or pulse methylprednisolone in the treatment of SSc-ILD. However, Nannini et al. [35] did not find any significant change in FVC or DLCO in a systematic review of 3 randomized trials and 6 observational studies. Similarly, Poormoghini et al. [36] did not detect a significant improvement, as defined by an increase >10% in FVC and/or DLCO, in CYC-treated SSc-ILD patients.

These results do not rule out that CYC is able to stabilize the progression of SSc-ILD as we previously suggested [37]. They also could induce to hypothesize that CYC is more effective in patients with clinically active disease such as in those with a recent decline in lung function [38]. After the pivotal study by Silver et al. [39], we also detected a significant improvement of lung physiology in 60% of patients enrolled for a significant decline of FVC and/or DLCO during the previous 6 months [40].

Mycophenolate mophetil (MMF), rituximab and Imatinib have also been investigated as first-line therapy in SSc-ILD patients. MMF has been investigated only in case-series and uncontrolled studies and has been found to be safe and effective in stabilizing lung function in patients with SSc-ILD [41]. These data suggest that MMF could be used as the first drug in active SSc-ILD patients. However, a recent case-control study comparing lung function changes in SSc-ILD patients treated either with MMF or CYC [42] pointed out in both groups a stabilization

**Table 1**

Clinical, serological, physiologic and radiologic features, detected at presentation and predictive of disease progression in SSc-ILD.

Feature	HR (95%CI)	Reference
FVC < 65%	3.18(1.76–5.72)	23
DLCO ≤ 55%	3.027(1.75–5.23)	23
HRCT fibrosis extent > 20%	3.0 (1.2–7.5)	21
Serum IL-6 > 7.67 pg/ml	2.58 (1.6–3.56)	22
Anti-Scl70 +	1.76 (1.22–2.52)	23
FVC 65–80%	1.71 (1.0–2.93)	23
dcSSc	1.69 (1.05–2.72)	23

of lung function after 2 years of follow-up, even if a greater deterioration of lung HRCT findings was pointed out in MMF-treated patients. Hopefully, the ongoing randomized control trial (Scleroderma Lung Study II) comparing head to head the efficacy of MMF and CYC as induction treatment for SSc-ILD will shed light on the differences in efficacy between these two drugs [43].

Rituximab has been reported to increase both FVC and DLCO in 8 patients after 2 years of follow-up [44], to preserve lung function in 20 patients with early diffuse disease [45] and to prevent the FVC decline in 9 patients with ILD, from EUSTAR database, compared to a worsening observed in matched controls [46]. Imatinib has been investigated in an open label, phase I/IIa pilot study by Khanna et al. [47], who detected a clinically non-significant improvement of FVC and total lung capacity.

### 3.1. Stem cell transplantation

Autologous hematopoietic stem cell transplantation has been compared to intravenous pulse CYC in dcSSc patients with a high skin score and heart or lung or kidney involvement [48]. This approach was associated with a statistically significant increase in total lung capacity and FVC in the 67 patients treated with transplantation with respect to those treated with CYC. Given the entry criteria and the high number of treatment-related deaths during the first year, this approach might be considered in selected SSc-ILD cases [48].

## 4. Can immunosuppressive treatment be stopped?

SSc-ILD patients enrolled in the Scleroderma Lung study experienced a beneficial effect on lung function, which continued to increase for 6 months after stopping CYC, but vanished 12 months after CYC discontinuation apart from a sustained effect on dyspnea [14]. These results raised the question, Could immunosuppression after CYC induction therapy lead to a better control of the disease? In this context, Berezne et al. [49] treated patients affected by a worsening ILD with 6 monthly CYC pulses followed by azathioprine for 18 months. They detected stable or improved FVC in 70% and 51.8% of SSc patients at 6 months and 2 years, respectively. Nevertheless, they applied the same protocol to both responsive and unresponsive patients.

We recently addressed this issue in a prospective uncontrolled study of patients with deteriorating lung function treated with low-dose pulse CYC as induction therapy and then assigned to receive azathioprine or MMF according to the response to the CYC [40]. The data suggest that azathioprine is effective as maintenance therapy in patients responsive to CYC, while MMF did not prevent further deterioration in about 66% of the patients unresponsive to CYC and preserved the decline in only 33% of them.

## 5. Which drug can be used in patients unresponsive to first-line therapy?

The choice of the therapeutic regimen to use when first-line treatment fails has been addressed by members of the Scleroderma Clinical Trials Consortium and Canadian Scleroderma Research Group, who did not reach a good agreement [50]. In addition to MMF [40], rituximab, imatinib and lung transplantation have been investigated in SSc-ILD unresponsive patients. Rituximab was found to significantly improve FVC after 12 months in a retrospective study of 50 ILD patients unresponsive to conventional immunosuppressive agents, including 8 patients with SSc-ILD [51]. Imatinib was tested in a prospective, 6-month, low-dose (200 mg/day), phase II study that included 30 SSc patients with active ILD, unresponsive to CYC [52], and resulted in an improvement or stabilization of lung disease in about 70% of patients.

Lung transplantation could be a viable therapeutic option in patients with end-stage lung disease [53]. To date, the indications and timing for referral to lung transplant in SSc patients are not clearly defined. Unfortunately, many comorbidities associated with SSc (skin ulcers, which

entail an increased risk of infections, severe esophageal dysfunction, cardiac conduction abnormalities, reduced renal filtration) represent contraindications for lung transplantation; consequently, the number of patients undergoing this procedure is still limited.

## 6. Conclusions

Immunosuppressive therapy in patients with SSc-ILD should be confined to those patients who are at risk of a progressive lung function decline, namely, all those, at admission, presenting an extent of lung fibrosis >20% at HRCT or an indeterminate extent plus an FVC < 70%, and all patients, during follow-up, experiencing a significant decrease of either DLCO (>15%) or FVC (>10%) or both whatever the extent of lung involvement. Pending the conclusions of the ongoing Scleroderma Lung Study II, CYC is the drug of first choice for the induction therapy of ILD-SSc. CYC pulses should be preferred to oral administration for a better safety profile. MMF can be considered in case of contraindication to CYC or to preserve fertility in younger patients. Maintenance immunosuppressive therapy is needed, even if the exact duration of immunosuppression is not defined. Azathioprine should be used in CYC responders. Low-dose imatinib or rituximab pulses can be tried in CYC non-responders. Lung transplantation can be considered in refractory and severe cases.

## Competing interests

The authors declare no conflict of interest

## List of abbreviations

ILD	interstitial lung disease
SSc	systemic sclerosis
CYC	cyclophosphamide
HRCT	high-resolution computed tomography
FVC	forced vital capacity
dcSSc	diffuse cutaneous systemic sclerosis
DLCO	lung diffusion for carbon monoxide
DLCO/VA	lung diffusing capacity for carbon monoxide divided by the alveolar volume
MMF	mycophenolate mofetil

## Take-home messages

- Only SSc-ILD patients at a high risk of progressive disease should be treated.
- Patients with a recent decline in lung function should be treated whatever the extent of lung involvement at HRCT.
- CYC is still the first-choice treatment for SSc-ILD, but there is a need for immunosuppressive maintenance therapy.
- Azathioprine can be used as maintenance therapy in CYC responder patients.
- Low-dose imatinib or rituximab pulses can be tried in CYC non-responders.
- Lung transplantation should be considered in refractory and severe cases.

## Acknowledgments

We thank Professor Christopher Denton and Doctor Svetlana Nihtyanova for the kindly provided raw data of their study and Mrs. Jean Ann Gilder (Scientific Communication srl., Naples, Italy) for revising and editing the text.

## References

- [1] Gabrielli A, Avvedimento EV, Scleroderma Krieg T. *N Engl J Med* 2009;360:1989–2003.
- [2] Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. *Autoimmun Rev* 2013;12:340–54.
- [3] Ferri C, Sebastiani M, Lo Monaco A, Iudici M, Giuggioli D, Furini F, et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature. *Autoimmun Rev* 2014;13:1026–34.
- [4] Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. *Ann Rheum Dis* 2007;66:940–4.
- [5] Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. *Rheumatology (Oxford)* 2009;48(Suppl. 3).
- [6] Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. *Eur Respir Rev* 2013;22:6–19.
- [7] Schurawitzki H, Stiglbauer R, Graninger W, Herold C, Pölzleitner D, Burghuber OC, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. *Radiology* 1990;176:755–9.
- [8] Wells AU, Denton CP. Interstitial lung disease in connective tissue disease—mechanisms and management. *Nat Rev Rheumatol* 2014;10:728–39.
- [9] Meier FM, Frommer KW, Dinsler R, Walker UA, Czirjak L, Denton CP, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. *Ann Rheum Dis* 2012;71:1355–60.
- [10] Steen VD, Conte C, Owens GR, Medsger Jr TA. Severe restrictive lung disease in systemic sclerosis. *Arthritis Rheum* 1994;37:1283–9.
- [11] Papiaris SA, Kagouridis K, Papadaki G, Kolilekas L, Manali ED. Treating CTDs related fibrotic ILDs by immunosuppressants: "facts and faults". *Lung* 2014;192:221–3.
- [12] Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. *N Engl J Med* 2006;354:2655–66.
- [13] Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. *Arthritis Rheum* 2006;54:3962–70.
- [14] Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. *Am J Respir Crit Care Med* 2007;176:1026–34.
- [15] Almeida I, Faria R, Vita P, Vasconcelos C. Systemic sclerosis refractory disease: from the skin to the heart. *Autoimmun Rev* 2011;10:693–701.
- [16] Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider FR, Varga J. Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis. How similar and distinct? *Arthritis Rheumatol* 2014;66:1967–78.
- [17] Steen VD, Powell DL, Medsger Jr TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. *Arthritis Rheum* 1988;31:196–203.
- [18] Briggs DC, Vaughan RW, Welsh KI, Myers A, duBois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. *Briggs Lancet* 1991;338:661–2.
- [19] Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. *Chest* 1998;114:801–7.
- [20] Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. *Am J Respir Crit Care Med* 2008;177:1248–54.
- [21] Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. *Rheumatology (Oxford)* 2013;52:155–60.
- [22] De Laurentis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. *J Rheumatol* 2013;40:435–46.
- [23] Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. *Arthritis Rheumatol* 2014;66:1625–35.
- [24] Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. *Arthritis Rheum* 2006;55:598–602.
- [25] Borous D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. *Am J Respir Crit Care Med* 2002;165:1581–6.
- [26] Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. *Arthritis Rheum* 2007;56:2005–12.
- [27] Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. *Chest* 2014;146:422–36.
- [28] Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. *Chest* 2008;134:601–5.
- [29] Steen VD. Autoantibodies in systemic sclerosis. *Semin Arthritis Rheum* 2005;35:35–42.
- [30] Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. *Am J Respir Crit Care Med* 2005;171:639–44.
- [31] Khanna D, Seibold JR, Wells A, Distler O, Allanore Y, Denton C, et al. Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. *Curr Rheumatol Rev* 2010;6:138–44.
- [32] Tashkin DP, Volkman ER, Tseng CH, Kim HJ, Goldin J, Clements P, et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. *Ann Rheum Dis* Dec 1 2014. <http://dx.doi.org/10.1136/annrheumdis-2014-206076>.
- [33] Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. *Arthritis Rheum* 2011;63:3078–85.
- [34] Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). *Ann Rheum Dis* 2009;68:620–8.
- [35] Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. *Arthritis Res Ther* 2008;10:R124. <http://dx.doi.org/10.1186/ar2534>.
- [36] Poomoghim H, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofanijed N. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. *Rheumatol Int* 2012;32:2431–44.
- [37] Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. *J Rheumatol* 2002;29:731–6.
- [38] Miniati I, Valentini G, Matucci Cerinic M. Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario. *Arthritis Res Ther* 2009;11:103. <http://dx.doi.org/10.1186/ar2576>.
- [39] Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. *J Rheumatol* 1993;20:838–44.
- [40] Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, et al. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. *Semin Arthritis Rheum* Sep 8 2014. <http://dx.doi.org/10.1016/j.semarthrit.2014.09.003>.
- [41] Tzouvelekas A, Galanopoulos N, Bouras E, Kolios G, Zacharis G, Ntoliou S, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. *Pulm Med* 2012;2012:143637.
- [42] Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfrikakis PP. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. *Lung* 2013;191:483–9.
- [43] [clinicaltrials.gov/ct2/show/NCT00883129](http://clinicaltrials.gov/ct2/show/NCT00883129).
- [44] Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinica C, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. *Clin Exp Rheumatol* 2012;30(Suppl. 71):S17–22.
- [45] Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. *Semin Arthritis Rheum* 2014 Sep 8. <http://dx.doi.org/10.1016/j.semarthrit.2014.09.002>.
- [46] Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. *Ann Rheum Dis* 2014 Jan 17. <http://dx.doi.org/10.1136/annrheumdis-2013-204522>.
- [47] Khanna D, Saggari R, Mayes MD, Abtin F, Clements PJ, Maranian P, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. *Arthritis Rheum* 2011;63:3540–6.
- [48] van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. *JAMA* 2014;311(11):2490–8.
- [49] Berezne A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. *J Rheumatol* 2008;35:1064–72.
- [50] Walker KM, Pope J, participating members of the Scleroderma Clinical Trial Consortium and Canadian Scleroderma Research Group. Treatment of systemic sclerosis complications: what to use when first-line treatment fails—a consensus of systemic sclerosis experts. *Semin Arthritis Rheum* 2012;42:42–55.
- [51] Keir GJ, Maher TM, Ming D, Abdullah R, de Laurentis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. *Respirology* 2014;19:353–9.
- [52] Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. *Arthritis Res Ther* 2014 Jul 8;16:R144. <http://dx.doi.org/10.1186/ar4606>.
- [53] De Cruz S, Ross D. Lung transplantation in patients with scleroderma. *Curr Opin Rheumatol* 2013;25:714–8.